공고 • Jun 30
Dalian BIO-CHEM Company Limited to Report First Half, 2026 Results on Aug 26, 2026 Dalian BIO-CHEM Company Limited announced that they will report first half, 2026 results on Aug 26, 2026 공고 • Jun 02
Liu Hongjun cancelled the acquisition of 10% stake in Dalian BIO-CHEM Company Limited (SHSE:603360) from Dalian Guangyao Zhixin Shuhong Enterprise Management Consulting Partnership Enterprise (L.P) and Dalian Tongyun Investment Co., Ltd. Liu Hongjun entered into share transfer agreement to acquire 10% stake in Dalian BIO-CHEM Company Limited (SHSE:603360) from Dalian Guangyao Zhixin Shuhong Enterprise Management Consulting Partnership Enterprise (L.P) and Dalian Tongyun Investment Co., Ltd. for approximately CNY 990 million on November 26, 2025. A cash consideration of CNY 992.81 million will be paid by the buyer. As part of consideration, CNY 992.81 million is paid towards common equity of Dalian BIO-CHEM Company Limited.
Liu Hongjun cancelled the acquisition of 10% stake in Dalian BIO-CHEM Company Limited (SHSE:603360) from Dalian Guangyao Zhixin Shuhong Enterprise Management Consulting Partnership Enterprise (L.P) and Dalian Tongyun Investment Co., Ltd. on May 31, 2026. Valuation Update With 7 Day Price Move • Jun 02
Investor sentiment deteriorates as stock falls 27% After last week's 27% share price decline to CN¥19.36, the stock trades at a forward P/E ratio of 42x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 286% over the past three years. Board Change • May 20
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Tian Bing Liu was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. 공고 • Apr 30
Dalian BIO-CHEM Company Limited (SHSE:603360) announces an Equity Buyback for CNY 100 million worth of its shares. Dalian BIO-CHEM Company Limited (SHSE:603360) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its class A shares. The company will repurchase its shares at a price not more than CNY 38.32 per share. The repurchased shares will be used for Employee Stock Ownership Plan or Equity Incentive. The plan will be valid for 12 months. 공고 • Apr 28
Dalian BIO-CHEM Company Limited, Annual General Meeting, May 18, 2026 Dalian BIO-CHEM Company Limited, Annual General Meeting, May 18, 2026, at 13:30 China Standard Time. Location: The Company's Meeting Room, Dalian, Liaoning China 공고 • Mar 30
Dalian BIO-CHEM Company Limited to Report Q1, 2026 Results on Apr 30, 2026 Dalian BIO-CHEM Company Limited announced that they will report Q1, 2026 results on Apr 30, 2026 공고 • Dec 26
Dalian BIO-CHEM Company Limited to Report Fiscal Year 2025 Results on Apr 24, 2026 Dalian BIO-CHEM Company Limited announced that they will report fiscal year 2025 results on Apr 24, 2026 공고 • Sep 30
Dalian BIO-CHEM Company Limited to Report Q3, 2025 Results on Oct 30, 2025 Dalian BIO-CHEM Company Limited announced that they will report Q3, 2025 results on Oct 30, 2025 공고 • Jun 30
Dalian BIO-CHEM Company Limited to Report First Half, 2025 Results on Aug 29, 2025 Dalian BIO-CHEM Company Limited announced that they will report first half, 2025 results on Aug 29, 2025 공고 • Apr 25
Dalian BIO-CHEM Company Limited, Annual General Meeting, May 15, 2025 Dalian BIO-CHEM Company Limited, Annual General Meeting, May 15, 2025, at 13:30 China Standard Time. Location: The Company's Meeting Room, Dalian, Liaoning China 공고 • Mar 28
Dalian BIO-CHEM Company Limited to Report Q1, 2025 Results on Apr 25, 2025 Dalian BIO-CHEM Company Limited announced that they will report Q1, 2025 results on Apr 25, 2025 공고 • Dec 27
Dalian BIO-CHEM Company Limited to Report Fiscal Year 2024 Results on Apr 25, 2025 Dalian BIO-CHEM Company Limited announced that they will report fiscal year 2024 results on Apr 25, 2025 Valuation Update With 7 Day Price Move • Oct 29
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥20.91, the stock trades at a trailing P/E ratio of 34.1x. Average trailing P/E is 35x in the Chemicals industry in China. Total returns to shareholders of 274% over the past three years. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to CN¥15.64, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 160% over the past three years. 공고 • Sep 30
Dalian BIO-CHEM Company Limited to Report Q3, 2024 Results on Oct 30, 2024 Dalian BIO-CHEM Company Limited announced that they will report Q3, 2024 results on Oct 30, 2024 공고 • Jun 28
Dalian BIO-CHEM Company Limited to Report First Half, 2024 Results on Aug 29, 2024 Dalian BIO-CHEM Company Limited announced that they will report first half, 2024 results on Aug 29, 2024 Valuation Update With 7 Day Price Move • May 22
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥17.56, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 18x in the Chemicals industry in China. Total returns to shareholders of 84% over the past three years. Reported Earnings • Apr 27
First quarter 2024 earnings released: EPS: CN¥0.27 (vs CN¥0.21 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.27 (up from CN¥0.21 in 1Q 2023). Revenue: CN¥338.3m (up 31% from 1Q 2023). Net income: CN¥98.3m (up 35% from 1Q 2023). Profit margin: 29% (in line with 1Q 2023). Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 14% per year. 공고 • Apr 27
Dalian BIO-CHEM Company Limited, Annual General Meeting, May 16, 2024 Dalian BIO-CHEM Company Limited, Annual General Meeting, May 16, 2024, at 13:30 China Standard Time. Location: The Company's Meeting Room, Dalian, Liaoning China 공고 • Mar 30
Dalian BIO-CHEM Company Limited to Report Q1, 2024 Results on Apr 26, 2024 Dalian BIO-CHEM Company Limited announced that they will report Q1, 2024 results on Apr 26, 2024 Valuation Update With 7 Day Price Move • Mar 12
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥11.96, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 29x in the Chemicals industry in China. Total returns to shareholders of 24% over the past three years. Valuation Update With 7 Day Price Move • Feb 23
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥10.19, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 28x in the Chemicals industry in China. Total returns to shareholders of 4.3% over the past three years. New Risk • Feb 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.6% average weekly change). Valuation Update With 7 Day Price Move • Jan 30
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥10.91, the stock trades at a trailing P/E ratio of 10.7x. Average trailing P/E is 31x in the Chemicals industry in China. Total returns to shareholders of 14% over the past three years. 공고 • Dec 30
Dalian BIO-CHEM Company Limited to Report Fiscal Year 2023 Results on Apr 26, 2024 Dalian BIO-CHEM Company Limited announced that they will report fiscal year 2023 results on Apr 26, 2024 Valuation Update With 7 Day Price Move • Nov 09
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥11.80, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 37x in the Chemicals industry in China. Total loss to shareholders of 3.6% over the past three years. Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.31 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.27 (down from CN¥0.31 in 3Q 2022). Revenue: CN¥277.8m (down 19% from 3Q 2022). Net income: CN¥93.1m (down 14% from 3Q 2022). Profit margin: 34% (up from 32% in 3Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. 공고 • Sep 30
Dalian BIO-CHEM Company Limited to Report Q3, 2023 Results on Oct 27, 2023 Dalian BIO-CHEM Company Limited announced that they will report Q3, 2023 results on Oct 27, 2023 Reported Earnings • Aug 29
Second quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.37 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.32 (down from CN¥0.37 in 2Q 2022). Revenue: CN¥315.2m (down 14% from 2Q 2022). Net income: CN¥117.2m (down 9.2% from 2Q 2022). Profit margin: 37% (up from 35% in 2Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. 공고 • Jun 28
Dalian BIO-CHEM Company Limited to Report First Half, 2023 Results on Aug 29, 2023 Dalian BIO-CHEM Company Limited announced that they will report first half, 2023 results on Aug 29, 2023 Reported Earnings • Apr 30
Full year 2022 earnings released: EPS: CN¥1.61 (vs CN¥1.00 in FY 2021) Full year 2022 results: EPS: CN¥1.61 (up from CN¥1.00 in FY 2021). Revenue: CN¥1.26b (up 25% from FY 2021). Net income: CN¥402.6m (up 61% from FY 2021). Profit margin: 32% (up from 25% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Buying Opportunity • Apr 18
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 14%. The fair value is estimated to be CN¥19.19, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 7.7%. Buying Opportunity • Dec 13
Now 22% undervalued Over the last 90 days, the stock is up 1.1%. The fair value is estimated to be CN¥21.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 7.7%. Revenue is forecast to grow by 21% in 2 years. Earnings is forecast to grow by 14% in the next 2 years. Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. 2 independent directors (6 non-independent directors). Independent Director Yongze Liu was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 30
Third quarter 2022 earnings released: EPS: CN¥0.43 (vs CN¥0.14 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.43 (up from CN¥0.14 in 3Q 2021). Revenue: CN¥343.6m (up 59% from 3Q 2021). Net income: CN¥108.4m (up 193% from 3Q 2021). Profit margin: 32% (up from 17% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10.0% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Reported Earnings • Aug 17
Second quarter 2022 earnings released: EPS: CN¥0.52 (vs CN¥0.27 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.52 (up from CN¥0.27 in 2Q 2021). Revenue: CN¥366.4m (up 43% from 2Q 2021). Net income: CN¥129.1m (up 81% from 2Q 2021). Profit margin: 35% (up from 28% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 18%, compared to a 42% growth forecast for the Chemicals industry in China. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 5 independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Mar 16
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥13.30, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 27x in the Chemicals industry in China. Total loss to shareholders of 6.0% over the past year. Reported Earnings • Mar 10
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: CN¥0.96 (up from CN¥0.85 in FY 2020). Revenue: CN¥1.01b (up 34% from FY 2020). Net income: CN¥251.5m (up 13% from FY 2020). Profit margin: 25% (down from 30% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Valuation Update With 7 Day Price Move • Nov 16
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥13.60, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 19x in the Chemicals industry in China. Total loss to shareholders of 27% over the past year. Reported Earnings • Aug 24
Second quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.15 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥256.8m (up 30% from 2Q 2020). Net income: CN¥71.3m (up 88% from 2Q 2020). Profit margin: 28% (up from 19% in 2Q 2020). The increase in margin was driven by higher revenue. Reported Earnings • Apr 25
First quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.34 in 1Q 2020) The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: CN¥218.4m (up 9.4% from 1Q 2020). Net income: CN¥51.8m (down 42% from 1Q 2020). Profit margin: 24% (down from 45% in 1Q 2020). The decrease in margin was driven by higher expenses. Reported Earnings • Apr 01
Full year 2020 earnings released: EPS CN¥0.85 (vs CN¥1.17 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥749.5m (down 14% from FY 2019). Net income: CN¥221.8m (down 28% from FY 2019). Profit margin: 30% (down from 35% in FY 2019). The decrease in margin was driven by lower revenue. Is New 90 Day High Low • Jan 28
New 90-day low: CN¥14.62 The company is down 19% from its price of CN¥18.00 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 23% over the same period. Is New 90 Day High Low • Jan 11
New 90-day low: CN¥14.64 The company is down 19% from its price of CN¥18.14 on 14 October 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period. Is New 90 Day High Low • Dec 19
New 90-day low: CN¥17.20 The company is down 4.0% from its price of CN¥17.91 on 21 September 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 5.0% over the same period. Reported Earnings • Oct 30
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥251.4m, down 7.3% from the prior year. Total revenue was CN¥837.2m over the last 12 months, up 15% from the prior year.